AI Infrastructure for Research Labs: IP, Control, and Staged Capacity

Private research labs — biotech, materials, computational chemistry, the R&D arms of industry — have become serious AI consumers, and their infrastructure question differs from both enterprises and universities: the data is unpublished and IP-bearing, the teams are small with no platform engineers, and the funding arrives in cycles. This page lays out the planning view those conditions demand: the four workload classes a lab actually runs, the IP boundary decision that shapes everything else, and the staged path from cloud validation to dedicated capacity with operating models a small team can sustain.

What a Research Lab Actually Runs: The Workload Classes

Private labs run four workload classes with different shapes: domain-model inference and fine-tuning (steady, moderate), simulation and molecular modeling (spiky, long-running), instrument-generated data processing (event-driven bursts around experiments), and exploratory analysis (small, sporadic) — the capacity plan is the allocation across these shapes, not one number.

Industry reporting on biotech AI compute catalogs the same use-case families — drug discovery, molecular simulation, clinical-adjacent analysis — and the catalog matters because each class buys capacity differently: the steady class justifies committed capacity, the spiky classes justify queue-and-burst designs, and the exploratory class should never own hardware. Lab missions differ — a wet-lab-adjacent informatics group and a computational-first team allocate differently — so inventory your own projects into the classes before sizing anything.

The IP Boundary: What Never Leaves the Lab

The lab's IP position decides its boundary: unpublished datasets, proprietary models, and candidate-molecule or patient-adjacent data typically justify a boundary where compute is dedicated and data paths are contracted — while public-data exploration and published-baseline work can run anywhere; the classification is a one-time exercise that pays off in every later capacity decision.

Private-infrastructure coverage for biomedical models states the motivation directly: dedicated GPU hosting exists to sidestep the data and IP concerns of public cloud, and hardware vendors position on-premise offerings for the same reason. The classification exercise is what turns that motivation into policy — two columns (inside the boundary, outside it), every project placed, reviewed annually. IP and confidentiality determinations involve counsel and funders; the infrastructure consequence of the determination is what this table frames: everything in the left rows can shop on price, everything in the right rows shops on control, and confusing the two columns is how labs either leak IP or massively overpay for elasticity they gated anyway.

The Staged Path: Cloud Validation to Dedicated Baseline

The staged path most labs follow: validate on cloud GPUs (pay for discovery speed), identify the steady baseline that emerges once projects stabilize, then move that baseline to dedicated capacity while keeping cloud for bursts — with the operating model (provider-managed versus self-run) chosen by whether a platform engineer exists on staff.

Biotech infrastructure guidance describes exactly this pattern — teams starting with cloud GPUs to validate before expanding — because the alternative (buying hardware on day one) bets scarce capital and scarce operating attention on a workload shape nobody has measured. The stage-3 decision has two parts: the capacity commitment, and the operating model. A lab with no platform engineer should choose provider-managed dedicated capacity — the lab writes workloads, the provider runs the fleet — because self-managing a GPU cluster is a second job nobody at a lab applied for. Dedicated environments such as OneSource Cloud's private AI infrastructure fit the stage-3, provider-managed cell: the boundary from the IP classification, the committed capacity from the baseline, and the operations on the provider. Labs with grant-purchased hardware skip stage one; the path describes the common sequence, not a rule.

FAQ

How small can a lab be before dedicated GPU capacity makes sense?

The trigger is a stable baseline, not headcount: once a lab's steady workload reliably consumes more than a part-time GPU's worth around the clock, dedicated capacity approaches cost parity — before that, cloud elasticity is cheaper even at high per-hour rates, because the lab is paying for zero between experiments.

How do grant and funding cycles change capacity commitments?

Align commitment terms to funding horizons: multi-year dedicated contracts need funding certainty across the term, so either phase commitments to grant cycles or use providers whose terms allow scaling down — and record the renewal decision date in the same calendar as the grant timeline, not the infrastructure one.

Instrument data arrives in bursts — how do we plan for that?

Treat instrument bursts as a separate workload class with elastic capacity: queue the burst, absorb it on rented or shared capacity, and reserve dedicated capacity for the steady classes — trying to size dedicated hardware for instrument peaks is the classic over-provisioning mistake in lab planning.